Sana Biotechnology
SANA
131 hedge funds and large institutions have $508M invested in Sana Biotechnology in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 27 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
1.58% less ownership
Funds ownership: 64.75% → 63.17% (-1.6%)
3% less funds holding
Funds holding: 135 → 131 (-4)
30% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 27
31% less capital inflows, than outflows
Capital inflows: $27.9M | Capital outflows: $40.5M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
84% less call options, than puts
Call options by funds: $303K | Put options by funds: $1.94M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.79M |
| 3 |
PFM Health Sciences
San Francisco,
California
|
+$2.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.32M |
| 5 |
BlackRock
New York
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.6M |
| 2 |
Public Sector Pension Investment Board (PSP Investments)
Montreal,
Quebec, Canada
|
-$6.33M |
| 3 |
Suvretta Capital Management
New York
|
-$5M |
| 4 |
Casdin Capital
New York
|
-$2.9M |
| 5 |
State of Michigan Retirement System
Lansing,
Michigan
|
-$2.66M |
SANA Hedge Fund Activity: Q4 2023 in Review
131 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q4 2023, worth a combined $508M — up 3% from $493M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of SANA and 19 opened new positions — a net loss of 8 holders — while 31 trimmed existing stakes and 50 added.
The largest buyer was Millennium Management, adding an estimated $6.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.6M.
- 131 institutional investors held Sana Biotechnology (SANA) as of Q4 2023, down from 135 in Q3 2023.
- Funds reported $508M of Sana Biotechnology stock for Q4 2023, up 3% quarter-over-quarter.
- 19 funds opened new Sana Biotechnology positions in Q4 2023 and 27 closed out, a net change of -8 holders.
- The largest Sana Biotechnology buyer in Q4 2023 was Millennium Management, an estimated $6.2M added.
- The largest Sana Biotechnology seller in Q4 2023 was T. Rowe Price Associates, an estimated $12.6M sold.
Based on aggregated 13F filings for Q4 2023.